Cascadian Therapeutics (CASC)

[lady glueck]

...Oncothyreon licensed a small molecule candidate, ARRY-380, from Array BioPharma Inc., which allows the company to redirect the resources originally intended for the PI3K inhibitor program to ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor, for the treatment of HER2-positive breast cancer.

Oncothyreon is a less straightforward story. Its valuation is particularly inexpensive with a $105M market cap, and that's what keeps us interested.

very informative BIOTECH Interview with Cantor Fitzgerald´s Mara Goldstein:
http://seekingalpha.com/article/1600852-6-oncology-focused-biotech-growth-engines-mara-goldstein?source=marketwatch